EDAP TMS SA, a global leader in robotic energy-based therapies, today announced that the Company will host a webcast that will feature a live procedure broadcast of its Focal One HIFU as a potential treatment for ablating cancer tissue in patients who are diagnosed with prostate cancer. The webcast is scheduled for Tuesday, April 18th at 12:00 p.m. PDT (3:00 p.m. EDT).
The procedure will be performed by Andre Abreu, MD and Amir H. Lebastchi, MD, Assistant Professors of Clinical Urology at Keck Medicine of the University of Southern California (USC).
“Our team is privileged to work closely with world-class academic medical centers like USC that are leading advances in the care of men with prostate cancer,” said Ryan Rhodes, Chief Executive Officer of EDAP U.S. “We believe focal therapy is the fastest growing emerging treatment option with the ability to offer excellent oncologic results while maintaining maximum quality of life. Teaching and sharing best practices in new clinical treatments are critical to ensuring more patients can avail themselves of the latest technologies with the absolute best results. We deeply appreciate the patient, physicians, staff and institution sharing this vision of teaching to help other centers adopt this advance with Focal One Robotic HIFU.”
“USC Urology is committed to developing new modalities that improve patient outcomes when facing prostate cancer,” said Dr. Inderbir Gill, urologist with Keck Medicine of USC and Chairman and Distinguished Professor of the Catherine and Joseph Aresty Department of Urology at Keck School of Medicine of USC. “We were the first U.S. institution to acquire EDAP’s innovative technology for using non-invasive ultrasound energy to precisely ablate prostate tissue, and we continue to lead in developing this emerging field through clinical research and patient care. We welcome colleagues from around the world to join our team in growing our collective knowledge of the best uses for robotic high intensity focused ultrasound to precisely treat appropriate patients with excellent results.”
For more information and to register for the webinar, please visit www.focalone.com.